시장보고서
상품코드
1873335

세계의 이식용 HLA 타이핑 시장

HLA Typing for Transplant

발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 194 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 이식용 HLA 타이핑 시장 규모는 2030년까지 15억 달러에 달할 전망

세계의 이식용 HLA 타이핑 시장은 2024년에 11억 달러로 추정되고 있으며, 2024-2030년의 분석 기간에 CAGR 5.3%로 성장하며, 2030년까지 15억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석 대상으로 한 부문의 하나인 비분자 어세이 기술은 4.4%의 CAGR을 기록하며, 분석 기간 종료시점으로 8억 6,910만 달러에 달할 것으로 예측됩니다. 분자 어세이 기술 부문의 성장률은 분석 기간에 6.7%의 CAGR로 추정되고 있습니다.

미국 시장은 2억 9,600만 달러로 추정되는 한편, 중국은 5.1%의 CAGR로 성장할 것으로 예측됩니다.

미국의 이식용 HLA 타이핑 시장은 2024년에 2억 9,600만 달러로 추정되고 있습니다. 세계 2위의 경제 규모를 자랑하는 중국은 2024-2030년의 분석 기간에 CAGR 5.1%로 추이하며, 2030년까지 2억 3,290만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역 시장으로는 일본과 캐나다를 들 수 있으며, 각각 분석 기간 중 5.1%, 4.3%의 CAGR로 성장할 것으로 예측됩니다. 유럽에서는 독일이 약 4.6%의 CAGR로 성장할 것으로 전망되고 있습니다.

세계의 이식용 HLA 타이핑 시장 - 주요 동향과 촉진요인 요약

HLA 타이핑이 장기이식 성공의 열쇠가 될 수 있는가?

HLA 타이핑(인간 백혈구 항원 타이핑)은 장기 이식의 기반 기술인데, 이 유전자 매칭 과정이 이식 성공에 매우 중요한 이유는 무엇인가? HLA 타이핑은 백혈구 표면의 특정 항원을 식별하여 면역체계가 자아와 비자아를 식별하는 데 중요한 역할을 하는 항원을 확인합니다. 이러한 항원은 장기-조직의 적합성에 필수적이며, 불일치는 이식 장기의 거부반응을 유발할 수 있습니다. 이식시 HLA 타이핑은 기증자와 수혜자의 면역학적 적합성을 최대한 높여 장기 거부반응의 위험을 줄이고 이식편 생존율을 향상시킵니다.

HLA 타이핑의 매력은 기증자와 수혜자의 면역 프로파일을 정밀하게 일치시켜 급성 또는 만성 거부반응과 같은 합병증을 줄일 수 있다는 점입니다. 이는 고형 장기 이식(신장, 간, 심장, 폐) 뿐만 아니라 조혈모세포 이식(골수)에서도 필수적이며, 이식편대숙주병(GVHD)을 예방하기 위해서는 정확한 HLA 적합성이 매우 중요합니다. 이식 전문의는 환자의 HLA 프로파일을 이해하고 최적의 공여자를 찾음으로써 이식 성공률을 높이고, 이식편을 손상시킬 수 있는 면역반응을 피할 수 있도록 도울 수 있습니다. 장기 이식에 대한 수요가 증가하고 기술이 발전함에 따라 HLA 타이핑은 생명을 살리는 의료 분야에서 최상의 결과를 얻기 위한 중요한 수단으로 자리매김하고 있습니다.

이식에서의 HLA 타이핑 기술 발전은 무엇인가?

기술 발전으로 HLA 타이핑의 정확성, 속도, 접근성이 크게 향상되어 이식시 공여자와 수혜자의 매칭 프로세스가 더욱 효율적이고 정밀하게 변모했습니다. 가장 중요한 발전 중 하나는 분자 기술, 특히 중합효소 연쇄반응(PCR) 기반 방법과 차세대 염기서열 분석(NGS)의 도입입니다. 기존에는 혈청학적 검사를 통해 HLA 항원을 확인했으나, 미세한 돌연변이 검출이나 고해상도 타이핑에는 한계가 있었습니다. PCR과 NGS로의 전환으로 HLA 타이핑의 해상도와 정확도가 극적으로 향상되어 몇 개의 염기 차이만 있는 특정 대립유전자를 식별할 수 있게 되었습니다. 이는 기증자와 수혜자의 적합성을 미세 조정하는 데 매우 중요합니다.

차세대 시퀀싱은 HLA 유전자좌에 대한 높은 처리량과 종합적인 유전 정보를 제공함으로써 HLA 타이핑에 혁명을 일으켰습니다. NGS는 여러 HLA 유전자를 병렬로 시퀀싱할 수 있으므로 이식팀은 공여자와 수혜자 모두의 HLA 대립유전자에 대해 더 자세히 이해할 수 있습니다. 이 고해상도 타이핑은 조혈모세포 이식에서 특히 중요합니다. 유전자 수준의 작은 불일치도 이식편대숙주병과 같은 심각한 합병증을 유발할 수 있기 때문입니다. NGS는 기존 방법으로는 검출이 어려운 희귀한 알러지나 신규 알러지를 식별할 수 있는 장점도 있으며, 기증자 선택의 정확도를 더욱 향상시키고 거부반응이나 면역 합병증 위험을 줄일 수 있습니다.

HLA 타이핑의 또 다른 큰 발전은 차세대 교차 매칭 검사의 활용입니다. 이는 항체 매개 거부반응의 가능성을 평가하는 데 도움이 됩니다. 이 검사는 첨단 유세포분석과 루미넥스 기술을 사용하여 수혈자의 혈액에서 기증자 특이적 항체(DSA)를 검출합니다. DSA는 항체 매개 거부반응의 주요 위험인자이며, 고해상도 HLA 타이핑과 상세한 교차시험을 결합하여 이식팀은 거부반응의 위험을 보다 정확하게 평가하고 환자의 필요에 따라 면역억제요법을 조정할 수 있습니다. 이러한 교차 시험 기술은 이식 계획에 대한 보다 역동적인 접근을 가능하게 하여 이식편 손실 가능성을 줄이고 장기적인 치료 결과를 개선할 수 있습니다.

고해상도 HLA 타이핑은 소프트웨어 툴과 바이오인포매틱스 플랫폼의 발전으로 인해 시퀀싱 데이터를 보다 빠르고 정확하게 해석할 수 있게 되었습니다. 고급 알고리즘이 대량의 시퀀싱 데이터를 실시간으로 분석할 수 있으므로 이식 센터는 기증자와 수혜자를 신속하게 매칭할 수 있습니다. 이러한 플랫폼은 프로세스를 가속화할 뿐만 아니라 인위적인 실수 가능성을 줄이고 HLA 매칭의 신뢰성을 향상시킵니다. 또한 바이오인포매틱스 툴은 HLA 에피토프 불일치(면역반응을 유발할 수 있는 HLA 분자의 미세한 차이)를 확인할 수 있으며, 기증자와 수혜자 간의 매칭을 더욱 정밀하게 할 수 있게 되었습니다.

인공지능(AI)과 머신러닝의 부상도 HLA 타이핑을 변화시킬 또 다른 분야입니다. AI 기반 시스템은 HLA 프로파일과 이식 결과의 방대한 데이터세트를 분석하여 기증자와 수혜자의 적합성을 보다 효과적으로 예측할 수 있도록 개발되고 있습니다. 이 시스템은 서로 다른 HLA 적합성 간의 잠재적 면역 반응을 모델링하여 기증자 선택 최적화 및 거부반응 위험 감소에 기여합니다. 예측 분석을 활용함으로써 AI는 궁극적으로 이식센터가 HLA 적합성 알고리즘을 더욱 정교화하여 완벽한 HLA 적합성을 얻지 못하는 경우에도 이식 성공률을 높일 수 있는 가능성을 가지고 있습니다.

신속한 HLA 타이핑 기법의 발전으로 응급 이식 사례에 대한 적기 적합성 제공도 가능해졌습니다. 환자의 상태가 빠르게 악화되는 경우, 기존의 HLA 타이핑 방법으로는 이식 성공을 보장하기에는 시간이 너무 오래 걸릴 수 있습니다. 그러나 신속한 PCR 기반 기술을 통해 HLA 유형핑 결과를 며칠이 아닌 몇 시간 만에 제공할 수 있게 되어 응급상황에서 신속한 매칭이 가능해졌습니다. 이는 특히 시간이 생명인 간, 심장, 폐 등 긴급한 수술이 필요한 간, 심장, 폐 이식에서 특히 중요합니다.

마지막으로 생체 공여자 이식에서 HLA 타이핑 기술의 발전은 신장 이식 등의 수술의 안전성과 성공률을 향상시키고 있습니다. HLA 타이핑은 기증자와 수혜자의 적합성을 높여 만성 거부반응의 위험을 줄이고, 기증자와 수혜자 모두의 장기적인 예후를 개선하는 데 기여하고 있습니다. 또한 생체 기증자끼리 신장을 교환하여 더 나은 HLA 적합성을 찾는 '신장교환 프로그램'에서도 신속하고 정밀한 HLA 타이핑으로 효과를 높여 거부반응의 위험을 줄이면서 더 많은 환자들이 적합한 기증자를 찾을 수 있게 되었습니다.

HLA 타이핑이 장기 이식의 성공에 필수적인 이유는 무엇인가?

HLA 타이핑이 장기 이식의 성공에 필수적인 이유는 기증자의 장기나 조직이 수혜자의 면역체계에 받아들여질 수 있는지 여부를 결정하는 데 핵심적인 역할을 하기 때문입니다. 세포 표면에 있는 HLA 분자는 이물질을 면역체계에 제시하는 역할을 하며, 부적합이 감지되면 면역반응을 일으킵니다. 장기이식에서 기증자의 HLA 항원이 수혜자의 HLA 항원과 크게 다를 경우, 수혜자의 면역체계가 장기를 이물질로 인식하고 공격을 시작할 수 있습니다. 이로 인해 급성 또는 만성 거부반응이 발생할 수 있습니다. 따라서 정확한 HLA 타이핑은 기증자와 수혜자를 보다 정밀하게 매칭하여 거부반응의 위험을 최소화하고 이식편의 장기 생존을 보장하는 데 도움이 됩니다.

신장 이식에서는 HLA 유형이 이식편 예후에 큰 영향을 미치는 것으로 나타났습니다. HLA 일치도가 높은 환자는 거부반응 발생 빈도가 낮고, 이식편 생존기간도 일치도가 낮은 장기를 이식받은 환자에 비해 길어지는 경향이 있습니다. 이는 과거 이식, 임신, 수혈로 인해 HLA 항원에 대한 항체를 획득한 '고감작 환자'에게 특히 중요합니다. 이러한 환자들은 적합도가 높은 기증자를 찾는 것이 더 어렵지만, 정밀한 HLA 타이핑과 탈감작 프로토콜을 결합하여 적합한 장기를 기증받아 항체 매개 거부반응의 위험을 줄일 수 있습니다.

조혈모세포이식(HSCT)에서는 HLA 적합성이 더욱 중요합니다. 공여자와 수혜자의 HLA 대립유전자 간 불일치는 이식된 면역세포가 수혜자의 조직을 공격하여 생명을 위협할 수 있는 이식편대숙주병(GVHD)을 유발할 수 있습니다. HLA 대립유전자의 작은 불일치도 심각한 GVHD를 유발할 수 있으므로 이러한 합병증의 위험을 줄이기 위해서는 완전 또는 거의 완전한 HLA 적합성을 찾는 것이 필수적입니다. 고해상도 HLA 타이핑은 주요 HLA 유전자좌(HLA-A, HLA-B, HLA-C, HLA-DRB1 등)와 마이너 유전자좌를 모두 신중하게 일치시키기 때문에 HSCT에서 매우 중요합니다. 결과적으로 HLA 타이핑은 이식된 줄기세포의 거부반응과 GVHD와 같은 심각한 합병증을 예방하는 데 도움이 됩니다.

HLA 타이핑은 간, 심장, 폐 이식의 성공에도 필수적입니다. 그러나 이러한 이식에 필요한 HLA 적합성 수준은 신장 이식이나 HSCT만큼 엄격하지 않을 수 있습니다. 이러한 경우, ABO 혈액형 적합성, 장기 크기 적합성 등 다른 요소도 중요합니다. 그러나 연구에 따르면 HLA 적합도가 높을수록 거부반응의 위험을 줄이고 이식편의 장기 생존율을 향상시켜 치료 결과를 개선할 수 있는 것으로 나타났습니다. 특히 공여 장기가 부족하고 신장 이식보다 생존율이 낮은 심장-폐 이식의 경우, 좋은 HLA 적합도를 달성하는 것이 장기 생존율에 큰 영향을 미칩니다.

신장 이식 등 생체 기증자 이식의 경우, HLA 타이핑을 통해 이식팀이 기증자와 수혜자의 적합성을 최적화하여 이식 성공 가능성을 높일 수 있습니다. 생체신장기증에서 HLA타이핑은 기증자와 수혜자의 적합성을 판단하기 위해 사용됩니다. 또한 완벽한 매칭이 이루어지지 않는 경우, HLA 타이핑은 신장 교환 페어링을 촉진하기 위해 활용됩니다. 이를 통해 생체 기증자 이식에 대한 유연한 접근이 가능해졌으며, 적합 후보자의 수를 늘려 환자가 더 빨리 이식을 받을 수 있도록 돕고 있습니다. 많은 경우, 사망한 기증자 장기보다 더 좋은 HLA 적합성을 얻을 수 있습니다.

장기이식이나 줄기세포 이식 외에도 HLA 타이핑은 수혈의학에서 매우 중요한 역할을 합니다. HLA 불일치는 수혈 관련 급성 폐 손상(TRALI)과 같은 수혈 관련 반응을 일으킬 수 있기 때문입니다. 혈소판 수혈은 HLA 타이핑을 통해 HLA 항체를 보유한 환자와 공여자를 매칭하여 수혈의 안전성과 유효성을 확보합니다. 미국 골수 기증자 프로그램(National Marrow Donor Program)과 같은 조직이 운영하는 골수 등록 기관에서는 HLA 타이핑을 통해 줄기세포 이식이 필요한 환자에게 잠재적인 기증자를 찾아내어 적합한 기증자를 찾을 수 있는 가능성을 크게 높입니다.

HLA 타이핑은 이식의 즉각적인 성공뿐만 아니라 수혜자의 장기적인 건강에도 중요합니다. HLA 적합성이 낮으면 만성 거부반응을 일으킬 수 있습니다. 이는 느리고 점진적인 과정이며, 결국 이식된 장기의 기능 장애를 초래할 수 있습니다. 만성 거부반응은 특히 신장이나 심장 이식시 장기적인 이식편 손실의 주요 원인 중 하나입니다. 기증자와 수혜자 간의 HLA 적합성을 높임으로써 이식센터는 만성 거부반응의 가능성을 줄이고, 수혜자의 평생 또는 적어도 수년 동안 이식 장기가 계속 기능할 수 있도록 보장할 수 있습니다.

이식용 HLA 타이핑 시장의 성장을 이끄는 요인은 무엇인가?

이식용 HLA 타이핑 시장의 성장은 장기 이식 및 줄기세포 이식에 대한 수요 증가, HLA 타이핑 기술의 발전, 만성질환의 유병률 증가, 전 세계 이식 등록 기관의 확대 등 몇 가지 주요 요인에 의해 주도되고 있습니다. 주요 촉진요인 중 하나는 말기신부전(ESRD), 간부전, 심부전, 혈액암 등의 질병 발생률 증가로 인한 장기 이식의 필요성 증가입니다. 이식 대기자 수가 지속적으로 증가함에 따라 기증자와 수혜자를 매칭하기 위한 정확하고 효율적인 HLA 타이핑에 대한 수요도 그만큼 증가하고 있습니다.

HLA 타이핑 기술의 발전, 특히 차세대 염기서열분석(NGS)의 도입도 시장 성장에 기여하고 있습니다. NGS를 통해 고해상도 HLA 타이핑은 보다 정확하고 신속하며 비용 효율적이어서 거부반응 위험을 최소화하고 치료 결과를 최적화하고자 하는 이식 센터에 최적화된 방법입니다. 전체 HLA 영역을 정밀하게 시퀀싱할 수 있는 능력은 기증자 선별을 개선하고, 특히 고도로 감작된 환자나 희귀 HLA 알레르기가 포함된 복잡한 사례에서 이식 성공률을 향상시키고 있습니다. 더 많은 이식 센터가 HLA 타이핑에 NGS를 채택함에 따라 이러한 고해상도 기술에 대한 수요가 증가하여 시장 확대를 촉진할 것으로 예측됩니다.

당뇨병, 고혈압, 암과 같은 만성질환의 유병률 증가도 HLA 타이핑 시장의 성장에 기여하는 요인입니다. 이러한 질병은 특히 신장, 간, 심장 등 장기 부전의 주요 원인이 되고 있습니다. 전 세계에서 이러한 질환으로 인한 부담이 계속 증가함에 따라 이식을 필요로 하는 환자 수도 증가하고 있습니다. HLA 타이핑은 이러한 환자들이 적합한 장기 및 줄기세포를 받을 수 있도록 보장하는 데 필수적이며, 이식 결과를 개선하고 거부반응 및 이식편 거부반응으로 인한 재이식의 필요성을 감소시킵니다.

골수 및 장기 기증자 등록제도의 확대도 HLA 타이핑 시장의 성장을 크게 견인하고 있습니다. 미국 'Be The Match'와 국제 등록기관 등에서는 특히 조혈모세포 이식을 위해 HLA 유형이 일치하는 기증자 수를 늘리기 위한 노력을 기울이고 있습니다. 잠재적 기증자로 등록하는 사람들이 늘어남에 따라 적합자를 찾기 위한 신속하고 정확한 HLA 타이핑의 필요성도 증가하고 있습니다. 특히 줄기세포 이식에 있으며, 자원 기증자 증가는 고해상도 HLA 타이핑에 대한 큰 수요를 창출하고 있습니다. 이식편 대 숙주병과 같은 합병증 위험을 줄이기 위해서는 정밀한 적합성이 매우 중요하기 때문입니다.

정밀의료와 맞춤의료에 대한 관심이 높아지는 것도 시장 성장을 촉진하는 요인입니다. 이식시 개별화 접근법의 핵심인 HLA 타이핑은 각 환자의 고유한 유전자 구성을 최적의 공여자와 일치시켜 최상의 결과를 보장하기 위해 필수적입니다. 유전체학의 발전과 이식 의학의 분자진단의 통합으로 HLA 비적합성 정도에 따른 개별화된 면역 억제 요법을 포함한 맞춤형 치료 계획에 대한 관심이 높아지고 있습니다. 이러한 정밀의료로의 전환으로 HLA 타이핑 서비스 수요는 더욱 확대될 것으로 예측됩니다.

장기 기증과 이식을 장려하는 정부의 구상과 의료 정책도 HLA 타이핑 시장의 성장에 기여하고 있습니다. 많은 국가들이 장기 기증에 대한 의식의 향상와 이식 인프라 개선을 위한 공중보건 캠페인에 투자하고 있습니다. 또한 장기 이식에 대한 규제 프레임워크와 상환 정책이 더욱 유리해지면서 환자들이 생명을 살리는 이식 수술을 받기 쉬워지고 있습니다. 정부와 의료계의 이러한 지원 강화로 이식을 필요로 하는 환자가 증가함에 따라 HLA타이핑에 대한 수요는 더욱 확대될 것으로 예측됩니다.

마지막으로 루미넥스(Luminex) 및 유세포분석 기술을 이용한 기증자 특이적 항체(DSA) 검출과 같은 교차 적합성 테스트의 발전은 종합적인 HLA 타이핑 및 교차 적합성 프로토콜에 대한 수요를 주도하고 있습니다. 이러한 기술을 통해 이식팀은 항체 매개 거부반응의 위험을 보다 정확하게 평가할 수 있으며, 기증자와 수혜자를 보다 정밀하게 매칭하여 이식 결과를 개선할 수 있습니다. 고해상도 HLA 타이핑과 결합된 교차 적합성 테스트의 활용 확대는 이식편의 장기 생존율 향상으로 이어져 시장 성장을 더욱 촉진하고 있습니다.

장기 및 줄기세포 이식에 대한 수요 증가, HLA 타이핑 기술의 발전, 그리고 전 세계에서 정밀의료로의 전환에 따라 HLA 타이핑 시장은 큰 폭의 성장이 예상됩니다. 의료 시스템이 이식 성공과 환자 치료 결과를 최우선시하는 가운데, HLA 타이핑은 적합성 확보, 거부반응 위험 감소, 이식 수혜자의 장기 생존율 향상을 위한 중요한 툴이 될 것입니다.

부문 :

기술(비분자 어세이, 분자 어세이), 제품·서비스(시약·소모품, 기기, 소프트웨어·서비스), 용도(진단, 조사)

조사 대상 기업의 예

  • Abbott Laboratories
  • Affymetrix, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Immucor, Inc.
  • Luminex Corporation
  • Qiagen NV
  • Thermo Fisher Scientific, Inc.

AI 통합

검증된 전문가 컨텐츠와 AI 툴을 통해 시장 및 경쟁 정보 분석을 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM이나 산업 전문 SLM에 대한 쿼리 방식을 대신하여 전 세계 도메인 전문가들이 엄선한 컨텐츠 리포지토리를 구축했습니다. 여기에는 비디오 전사, 블로그, 검색엔진 조사, 그리고 방대한 양의 기업, 제품/서비스, 시장 데이터가 포함됩니다.

관세 영향 계수

이번 보고서에는 Global Industry Analysts가 예측한 본사 소재지, 생산기지, 수출입(완제품 및 OEM)에 따른 기업의 경쟁력 변화에 따라 지역 시장에 미치는 관세의 영향을 반영했습니다. 이러한 복잡하고 다면적인 시장 현실은 수입원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학을 통해 경쟁사들에게 영향을 미칠 것입니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 세계의 기타 지역

제4장 경쟁

KSA 25.11.27

Global HLA Typing for Transplant Market to Reach US$1.5 Billion by 2030

The global market for HLA Typing for Transplant estimated at US$1.1 Billion in the year 2024, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Non-Molecular Assay Technology, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$869.1 Million by the end of the analysis period. Growth in the Molecular Assay Technology segment is estimated at 6.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$296.0 Million While China is Forecast to Grow at 5.1% CAGR

The HLA Typing for Transplant market in the U.S. is estimated at US$296.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$232.9 Million by the year 2030 trailing a CAGR of 5.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.1% and 4.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global HLA Typing for Transplant Market - Key Trends and Drivers Summarized

Is HLA Typing the Key to Success in Organ Transplantation?

HLA typing, or human leukocyte antigen typing, is a cornerstone of organ transplantation, but why is this genetic matching process so vital for transplant success? HLA typing involves identifying specific antigens on the surface of white blood cells that play a critical role in the immune system’s ability to recognize self from non-self. These antigens are crucial in organ and tissue compatibility, as mismatches can lead to rejection of the transplanted organ. In transplantation, HLA typing ensures that the donor and recipient are as immunologically compatible as possible, reducing the risk of organ rejection and improving graft survival.

The appeal of HLA typing lies in its ability to match the donor’s and recipient’s immune profiles closely, reducing complications such as acute or chronic rejection. It is essential not only for solid organ transplants (kidneys, liver, heart, lungs) but also for hematopoietic stem cell transplants (bone marrow), where precise HLA matching is critical to prevent graft-versus-host disease (GVHD). By understanding the patient’s HLA profile and finding the best donor match, transplant specialists can improve the success rates of transplants and help patients avoid the immune responses that might otherwise compromise the graft. As the demand for organ transplants grows and technology advances, HLA typing remains a critical tool for achieving the best possible outcomes in this life-saving medical field.

How Has Technology Advanced HLA Typing for Transplantation?

Technological advancements have significantly improved the accuracy, speed, and accessibility of HLA typing, transforming it into a more efficient and precise process for matching donors and recipients in transplantation. One of the most important developments has been the introduction of molecular techniques, particularly polymerase chain reaction (PCR)-based methods and next-generation sequencing (NGS). In the past, serological testing was used to identify HLA antigens, but these methods had limitations in detecting subtle variations and providing high-resolution typing. The shift to PCR and NGS has dramatically improved the resolution and accuracy of HLA typing, allowing for the identification of specific alleles that differ by only a few nucleotides, which can be critical in fine-tuning donor-recipient compatibility.

Next-generation sequencing has revolutionized HLA typing by providing high-throughput, comprehensive genetic information about HLA loci. NGS allows for the sequencing of multiple HLA genes in parallel, giving transplant teams a more detailed understanding of both donor and recipient HLA alleles. This high-resolution typing is particularly important in hematopoietic stem cell transplants, where even small mismatches at the genetic level can lead to serious complications like graft-versus-host disease. NGS also has the advantage of identifying rare or novel alleles that might not be detectable with older methods, further enhancing the precision of donor selection and reducing the risk of rejection or immune complications.

Another major advancement in HLA typing is the use of next-generation crossmatch assays, which help assess the potential for antibody-mediated rejection. These assays use advanced flow cytometry and Luminex technology to detect donor-specific antibodies (DSAs) in the recipient’s blood. DSAs are a major risk factor for antibody-mediated rejection, and by combining high-resolution HLA typing with detailed crossmatch testing, transplant teams can more accurately assess the risk of rejection and tailor immunosuppressive therapies to the patient’s needs. These crossmatch technologies allow for a more dynamic approach to transplant planning, reducing the likelihood of graft loss and improving long-term outcomes.

High-resolution HLA typing has also benefited from advances in software tools and bioinformatics platforms, which enable faster, more accurate interpretation of sequencing data. Sophisticated algorithms can now analyze large volumes of sequencing data in real time, ensuring that transplant centers can quickly match donors and recipients. These platforms not only speed up the process but also reduce the likelihood of human error, improving the reliability of HLA matching. Additionally, bioinformatics tools can identify HLA epitope mismatches-small differences in HLA molecules that might trigger an immune response-allowing for even more refined matching between donors and recipients.

The rise of artificial intelligence (AI) and machine learning is another area transforming HLA typing. AI-driven systems are being developed to predict donor-recipient compatibility more effectively by analyzing large datasets of HLA profiles and transplant outcomes. These systems can model the potential immune responses between different HLA matches, helping to optimize donor selection and reduce the risk of rejection. By leveraging predictive analytics, AI could eventually allow transplant centers to refine HLA matching algorithms further, improving transplant success rates even in cases where perfect HLA matches are not available.

Advances in rapid HLA typing methods have also made it possible to provide timely matches for urgent transplant cases. In cases where a patient’s condition deteriorates quickly, traditional methods of HLA typing may take too long to ensure a successful transplant. However, rapid PCR-based techniques can now provide HLA typing results in a matter of hours rather than days, allowing for faster matching in emergency situations. This is particularly important in liver, heart, or lung transplants, where time is of the essence and patients are often in critical need of immediate surgery.

Finally, advancements in HLA typing for living donor transplants have improved the safety and success of procedures such as kidney transplants. By ensuring a closer match between living donors and recipients, HLA typing has reduced the risk of chronic rejection, leading to better long-term outcomes for both donor and recipient. Additionally, paired kidney exchanges, where living donors swap kidneys to find better HLA matches, have been made more effective through rapid and precise HLA typing, helping more patients find suitable donors while maintaining low rejection risks.

Why Is HLA Typing Critical for Successful Organ Transplants?

HLA typing is critical for successful organ transplants because it plays a central role in determining whether a donor’s organ or tissue will be accepted by the recipient’s immune system. The HLA molecules on the surface of cells are responsible for presenting foreign substances to the immune system, triggering an immune response if a mismatch is detected. In organ transplantation, if the donor’s HLA antigens are too different from the recipient’s, the recipient’s immune system may recognize the organ as foreign and mount an attack, leading to acute or chronic rejection. Therefore, accurate HLA typing helps match donors and recipients more precisely, minimizing the risk of rejection and ensuring long-term graft survival.

In kidney transplantation, HLA typing has been shown to significantly influence graft outcomes. Patients with a high degree of HLA matching tend to experience fewer rejection episodes, and their grafts tend to last longer compared to patients with poorly matched organs. This is especially important in highly sensitized patients-those who have developed antibodies against HLA antigens due to prior transplants, pregnancies, or blood transfusions. For these patients, finding a well-matched donor is more challenging, but precise HLA typing, combined with desensitization protocols, can help them receive compatible organs and reduce the risk of antibody-mediated rejection.

In hematopoietic stem cell transplants (HSCT), HLA matching is even more critical. Mismatches between donor and recipient HLA alleles can lead to graft-versus-host disease (GVHD), a potentially life-threatening condition where the transplanted immune cells attack the recipient’s tissues. Even minor mismatches in HLA alleles can result in severe GVHD, so finding a perfect or near-perfect HLA match is essential for reducing the risk of this complication. High-resolution HLA typing is crucial in HSCT to ensure that both the major HLA loci (such as HLA-A, HLA-B, HLA-C, and HLA-DRB1) and minor loci are carefully matched. As a result, HLA typing helps prevent both rejection of the transplanted stem cells and serious complications like GVHD.

HLA typing is also essential for the success of liver, heart, and lung transplants, although the level of HLA matching required for these transplants may not be as strict as for kidney or HSCT. In these cases, other factors like ABO blood type matching and organ size compatibility are also important. However, research has shown that better HLA matching can still improve outcomes by reducing the risk of rejection and improving graft longevity. In particular, for heart and lung transplants, where donor organs are scarce and survival rates are lower than in kidney transplants, achieving a good HLA match can significantly impact long-term survival.

For living donor transplants, such as in kidney transplantation, HLA typing enables transplant teams to optimize the match between donors and recipients, improving the likelihood of success. In living kidney donation, HLA typing is used to determine the compatibility between donor and recipient, and in some cases, where a perfect match is not available, HLA typing is used to facilitate paired kidney exchanges. This allows for a more flexible approach to living donor transplants, increasing the number of possible matches and helping patients receive transplants sooner, often with better HLA matches than deceased donor organs.

Beyond organ and stem cell transplantation, HLA typing also plays a critical role in transfusion medicine, where HLA mismatches can cause transfusion-related reactions such as transfusion-related acute lung injury (TRALI). In platelet transfusions, HLA typing is used to match donors with patients who have developed HLA antibodies, ensuring that transfusions are safer and more effective. In bone marrow registries, such as those run by organizations like the National Marrow Donor Program, HLA typing is used to identify potential donors for patients in need of stem cell transplants, significantly improving the chances of finding compatible matches.

HLA typing is not only important for the immediate success of the transplant but also for the long-term health of the recipient. Poor HLA matching can lead to chronic rejection, a slow and progressive process that eventually causes the transplanted organ to fail. Chronic rejection is one of the leading causes of late graft loss, particularly in kidney and heart transplants. By improving the HLA match between donor and recipient, transplant centers can reduce the likelihood of chronic rejection, ensuring that the transplant remains functional for many years, if not for the lifetime of the recipient.

What Factors Are Driving the Growth of the HLA Typing for Transplant Market?

The growth of the HLA typing for transplant market is driven by several key factors, including the rising demand for organ and stem cell transplants, advancements in HLA typing technologies, the increasing prevalence of chronic diseases, and the expansion of transplant registries worldwide. One of the primary drivers is the growing need for organ transplants, fueled by the rising incidence of conditions such as end-stage renal disease (ESRD), liver failure, heart failure, and hematological cancers. As the number of patients waiting for transplants continues to rise, the demand for accurate and efficient HLA typing to match donors and recipients has grown correspondingly.

Advancements in HLA typing technologies, particularly the adoption of next-generation sequencing (NGS), have also contributed to market growth. NGS has made high-resolution HLA typing more accurate, faster, and cost-effective, making it the preferred method for transplant centers seeking to minimize rejection risks and optimize outcomes. The ability to sequence entire HLA regions with high precision has improved donor selection and increased the success rates of transplants, particularly in complex cases involving highly sensitized patients or rare HLA alleles. As more transplant centers adopt NGS for HLA typing, the demand for these high-resolution techniques is expected to increase, driving market expansion.

The increasing prevalence of chronic diseases, such as diabetes, hypertension, and cancer, is another factor contributing to the growth of the HLA typing market. These conditions are leading causes of organ failure, particularly for kidneys, livers, and hearts. As the global burden of these diseases continues to rise, so does the number of patients requiring transplants. HLA typing is essential for ensuring that these patients receive compatible organs or stem cells, improving transplant outcomes and reducing the need for re-transplantation due to rejection or graft failure.

The expansion of bone marrow and organ donor registries is also playing a significant role in driving the HLA typing market. Organizations such as Be The Match in the United States and international registries are working to increase the number of HLA-typed donors, particularly for hematopoietic stem cell transplants. As more individuals register as potential donors, the need for rapid and accurate HLA typing to identify matches grows. In particular, the rise of volunteer donors for stem cell transplants has created a significant demand for high-resolution HLA typing, as precise matching is critical for reducing the risk of complications like graft-versus-host disease.

The growing emphasis on precision medicine and personalized healthcare is another factor driving market growth. HLA typing is central to the personalized approach in transplantation, where each patient’s unique genetic makeup must be matched to the most suitable donor to ensure the best possible outcome. Advances in genomics and the integration of molecular diagnostics in transplant medicine have increased the focus on individualized treatment plans, which include tailored immunosuppressive regimens based on the degree of HLA mismatch. This shift toward precision medicine is expected to further expand the demand for HLA typing services.

Government initiatives and healthcare policies promoting organ donation and transplantation are also contributing to the growth of the HLA typing market. Many countries are investing in public health campaigns to raise awareness about organ donation and improve the infrastructure for transplantation. Additionally, regulatory frameworks and reimbursement policies for organ transplants are becoming more favorable, making it easier for patients to access life-saving transplant procedures. This increased support from governments and healthcare systems is expected to drive further growth in the demand for HLA typing as more patients are referred for transplantation.

Finally, advancements in crossmatch testing, including the use of Luminex and flow cytometry techniques to detect donor-specific antibodies (DSAs), are driving demand for comprehensive HLA typing and crossmatching protocols. These techniques allow transplant teams to assess the risk of antibody-mediated rejection more accurately, improving transplant outcomes by enabling more precise donor-recipient matching. The increasing use of crossmatch testing, combined with high-resolution HLA typing, is leading to better long-term graft survival rates, further supporting market growth.

With the increasing need for organ and stem cell transplants, technological advancements in HLA typing, and the global shift toward precision medicine, the HLA typing market is poised for significant growth. As healthcare systems continue to prioritize transplant success and patient outcomes, HLA typing will remain a critical tool for ensuring compatibility, reducing rejection risks, and improving the long-term survival of transplant recipients.

SCOPE OF STUDY:

The report analyzes the HLA Typing for Transplant market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Non-Molecular Assay, Molecular Assay); Products & Services (Reagents & Consumables, Instruments, Software & Services); Application (Diagnostics, Research)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

  • Abbott Laboratories
  • Affymetrix, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Immucor, Inc.
  • Luminex Corporation
  • Qiagen NV
  • Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • HLA Typing for Transplant - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Organ Transplantation Drives Growth in HLA Typing Market
    • Expansion of Bone Marrow and Stem Cell Transplant Programs Spurs Adoption of HLA Typing for Transplantation
    • Role of HLA Typing in Supporting Research on Immunotherapy and Autoimmune Diseases Expands Market Reach
    • Role of HLA Typing in Enhancing Success Rates in Kidney and Liver Transplants Fuels Market Growth
    • Growth in Use of HLA Typing in Allogeneic and Autologous Transplantation Strengthens Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Reagents & Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Non-Molecular Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Non-Molecular Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Non-Molecular Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Molecular Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Molecular Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Molecular Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 22: World HLA Typing for Transplant Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for HLA Typing for Transplant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for HLA Typing for Transplant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for HLA Typing for Transplant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • HLA Typing for Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • JAPAN
    • HLA Typing for Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • CHINA
    • HLA Typing for Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • EUROPE
    • HLA Typing for Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for HLA Typing for Transplant by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for HLA Typing for Transplant by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for HLA Typing for Transplant by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
  • FRANCE
    • HLA Typing for Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • GERMANY
    • HLA Typing for Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 83: Germany Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Germany 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 92: Italy Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Italy 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 95: Italy Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • HLA Typing for Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 101: UK Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UK Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: UK 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Rest of Europe 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Rest of Europe 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Rest of Europe 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • HLA Typing for Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Asia-Pacific 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Asia-Pacific 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Asia-Pacific 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 128: Rest of World Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of World Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of World 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of World Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of World Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of World 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of World 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제